Intellia Therapeutics (NTLA) Shares Outstanding (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Shares Outstanding data on file, last reported at $120.4 million in Q1 2026.

• Quarterly Shares Outstanding rose 16.33% year-over-year to $120.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.4 million (up 16.33% YoY) and the FY2025 annual result came in at $116.3 million, up 14.0% from the prior year.
• Shares Outstanding improved to $120.4 million in Q1 2026 per NTLA's latest filing, from $116.3 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $120.4 million in Q1 2026 and bottomed at $24316.0 in Q3 2022.
• The 5-year median for Shares Outstanding is $89.1 million (2023), against an average of $80.2 million.
• The widest annual swing landed in 2023, when Shares Outstanding soared 366316.44%; it then tumbled 99.9% in 2024.
• Tracing NTLA's Shares Outstanding over 5 years: stood at $87.1 million in 2022, then rose by 6.77% to $93.0 million in 2023, then rose by 9.71% to $102.0 million in 2024, then advanced by 14.0% to $116.3 million in 2025, then gained by 3.55% to $120.4 million in 2026.
• Per Business Quant, the three latest NTLA Shares Outstanding figures stand at $120.4 million (Q1 2026), $116.3 million (Q4 2025), and $115.8 million (Q3 2025).

Peer Comparison